N1-Methylnicotinamide urinary output in multiple sclerosis affected patients.
This brief report develops the ideas of some previous works underlying a possible functional disequilibrium of tryptophan metabolism in patients affected by Multiple Sclerosis (M.S.) and in animals with experimental allergic encephalomyelitis. So, the urinary excretion of one of the terminal metabolites of the kynurenine pathway of tryptophan, the N1-Methylnicotinamide has been confronted in M.S. patients and in healthy volunteers, in order to put in evidence a possible alteration of the same in M.S. patients. The A.A. could not find any significant difference of the N1-Methylnicotinamide urinary output between controls and M.S. patients; afterwards they have critically revised this result.